secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2022-10-12T23:59:59+00:00
Accession:  0001831283-22-000064
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio halts infigratinib CCA program after Helsinn exits US market
--------------------------------------------------------------------

- Helsinn Healthcare SA permanently discontinues Truseltiq (infigratinib) in US; plans to withdraw NDA for business reasons.
- BridgeBio closing global Phase 3 PROOF-301 trial of infigratinib in first-line cholangiocarcinoma (CCA).
- LianBio terminating all CCA development in China; no longer pursuing infigratinib for CCA in licensed territories.
- LianBio will continue supporting existing patients under the Hainan Named Patient Program.
- LianBio expects to continue Phase 2a trial of infigratinib in gastric cancer and other FGFR-altered solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000064/0001831283-22-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000064/lian-20221012.htm
  HTML page:      https://secwatch.observer/filing/0001831283-22-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer